A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : ICER

Search Conditions:
Search Keyword : ICER
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: ICER
Appearance Frequency: 3518 time(s)
Long forms: 40

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
incremental cost-effectiveness ratio
(3173 times)
Neoplasms
(333 times)
QALY (925 times)
QALYs (912 times)
WTP (153 times)
1997 Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
inducible cAMP early repressor
(201 times)
Neurology
(39 times)
CREM (38 times)
CREB (37 times)
CRE (32 times)
1993 Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor.
Institute for Clinical and Economic Review
(73 times)
Managed Care Programs
(35 times)
QALY (7 times)
NCCN (4 times)
NIHCM (4 times)
2010 An integrated evidence rating to frame comparative effectiveness assessments for decision makers.
incremental cost per QALY saved
(20 times)
Science
(5 times)
QALYs (12 times)
WTP (4 times)
QALY (3 times)
2012 A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
incremental CE ratio
(9 times)
Medical Informatics
(2 times)
CE (8 times)
QALY (3 times)
QALYs (3 times)
2007 The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
incremental cost per quality adjusted life years
(3 times)
Neoplasms
(1 time)
HCV (1 time)
IMRT (1 time)
NHS (1 time)
2012 Cost-effectiveness and population outcomes of general population screening for hepatitis C.
inducible cyclic adenosine monophosphate early repressor
(3 times)
Molecular Biology
(2 times)
ALI (1 time)
alpha-CGRP (1 time)
BM (1 time)
1999 The inducible cyclic adenosine monophosphate early repressor (ICER) in the pituitary intermediate lobe: role in the stress response.
immobilized capillary enzyme reactor
(2 times)
Chemistry Techniques, Analytical
(1 time)
AChE (1 time)
AD (1 time)
BChE (1 time)
2015 Label-free assay based on immobilized capillary enzyme reactor of Leishmania infantum nucleoside triphosphate diphosphohydrolase (LicNTPDase-2-ICER-LC/UV).
incremental cost per avoided case
(2 times)
Health Services
(1 time)
AD (2 times)
MOH (2 times)
CEA (1 time)
2010 Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children.
10  Individual Child Engagement Record
(2 times)
Developmental Disabilities
(2 times)
--- 2006 A measure of engagement for children with intellectual disabilities in early childhood settings: a preliminary study.
11  case in all four countries
(1 time)
World Health
(1 time)
MTCT (1 time)
2020 Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study.
12  III, strategy VI was more costly and more effective
(1 time)
Obstetrics
(1 time)
EFI (1 time)
2020 Use of the EFI score in endometriosis-associated infertility: A cost-effectiveness study.
13  including a health sector cost
(1 time)
Malaria
(1 time)
RDTs (1 time)
2015 Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan.
14  increase compared with the base case
(1 time)
Tropical Medicine
(1 time)
IRS (1 time)
ITN (1 time)
2018 Cost-Effectiveness of Indoor Residual Spraying of Households with Insecticide for Malaria Prevention and Control in Tanzania.
15  increased the net cost per life-year gained
(1 time)
Allergy and Immunology
(1 time)
--- 2006 Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
16  incremental CER
(1 time)
Liver Neoplasms
(1 time)
CEA (1 time)
CER (1 time)
FDA (1 time)
2020 Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis.
17  Incremental cost effectiveness ratio was calculated
(1 time)
Radiotherapy
(1 time)
C-PCI (1 time)
HA (1 time)
LS-SCLC (1 time)
2017 Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer.
18  incremental cost of -33,609/patient
(1 time)
Economics, Pharmaceutical
(1 time)
MS (1 time)
QALY (1 time)
SOC (1 time)
2016 A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
19  incremental cost per additional QALY
(1 time)
Reproductive Medicine
(1 time)
LNG-IUS (1 time)
QALYs (1 time)
2006 A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia.
20  incremental cost-effectiveness ratio per avoided case of atopic dermatitis
(1 time)
Nutritional Sciences
(1 time)
CEA (1 time)
EHF (1 time)
SF (1 time)
2012 Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses.
21  incremental cost-effectiveness ratio per gained additional QALY
(1 time)
Therapeutics
(1 time)
GDPpc (1 time)
MS-CD (1 time)
PSA (1 time)
2019 Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
22  Incremental Costs and Effectiveness Ratio
(1 time)
Endocrine System Diseases
(1 time)
BMI (1 time)
CDM (1 time)
CSII (1 time)
2021 Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.
23  Incremental costs per expected life-year
(1 time)
Pharmacy
(1 time)
ACE (1 time)
OTC (1 time)
2011 [Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension].
24  Incremental costs, effectiveness, and cost-effectiveness ratios
(1 time)
Neoplasms
(1 time)
QALY (1 time)
SABR (1 time)
SC (1 time)
2021 Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease.
25  incremental expense-efficacy rate
(1 time)
Medicine
(1 time)
CBRS (1 time)
HBRS (1 time)
2015 Home-based versus center-based care in children with cerebral palsy: a cost-effectiveness analysis.
26  incremental ratio has
(1 time)
Pharmacology
(1 time)
QoL (1 time)
RA (1 time)
2018 Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines.
27  Incremental-Effectiveness Ratio
(1 time)
Communicable Diseases, Emerging
(1 time)
PC (1 time)
SAC (1 time)
USD (1 time)
2021 Control programs for strongyloidiasis in areas of high endemicity: an economic analysis of different approaches.
28  indicated CO to be more expensive at limited
(1 time)
Dentistry
(1 time)
CO (1 time)
GH (1 time)
2021 Cost-effectiveness of glass hybrid versus composite in a multi-country randomized trial.
29  inducible cAMP response early repressor
(1 time)
Endocrinology
(1 time)
AANAT (1 time)
mRNA (1 time)
PD (1 time)
1999 Ovine arylalkylamine N-acetyltransferase in the pineal and pituitary glands: differences in function and regulation.
30  inducible repressor
(1 time)
Hematologic Diseases
(1 time)
ALL (1 time)
AML (1 time)
CREB (1 time)
2009 CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis.
31  influenced the primary outcome
(1 time)
Psychology
(1 time)
AChEI (1 time)
AD (1 time)
FDG (1 time)
2015 Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
32  Information created to evade reality
(1 time)
Pharmacology
(1 time)
--- 2006 Information created to evade reality (ICER): things we should not look to for answers.
33  Institute for Clinical and Effectiveness Review
(1 time)
Health Policy
(1 time)
BSC (1 time)
CUA (1 time)
QALY (1 time)
2021 An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
34  internal strategy showed some evidence of cost-effectiveness
(1 time)
Therapeutics
(1 time)
CTA (1 time)
ICERs (1 time)
2013 Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
35  intervention using the same basic model
(1 time)
Traumatology
(1 time)
ICERs (1 time)
NZ (1 time)
QALYs (1 time)
2018 Exercise programmes to prevent falls among older adults: modelling health gain, cost-utility and equity impacts.
36  Intervention was associated with significantly higher costs
(1 time)
Nutritional Sciences
(1 time)
ONS (1 time)
QALYs (1 time)
SF (1 time)
2011 Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study.
37  intervention was low, except for the group with moderate depression
(1 time)
Psychiatry
(1 time)
CG (1 time)
QALY (1 time)
2020 Cost-effectiveness of guideline-based stepped and collaborative care versus treatment as usual for patients with depression - a cluster-randomized trial.
38  irinotecan
(1 time)
Technology
(1 time)
--- 2012 The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
39  isoform of cAMP-responsive element binding modulator
(1 time)
Endocrinology
(1 time)
P450arom (1 time)
SMase (1 time)
2006 Tumor necrosis factor-alpha activates transcription of inducible repressor form of 3',5'-cyclic adenosine 5'-monophosphate-responsive element binding modulator and represses P450 aromatase and inhibin alpha-subunit expression in rat ovarian granulosa cells by a p44/42 mitogen-activated protein kinase-dependent mechanism.
40  iterated conditional entropy reduction
(1 time)
Diagnostic Imaging
(1 time)
EB (1 time)
MR (1 time)
MRF (1 time)
2007 Feature-preserving MRI denoising: a nonparametric empirical Bayes approach.